Donald Deieso

Donald Deieso is a healthcare and clinical-research executive associated with Arsenal Capital Partners as a Senior Advisor. Arsenal described him in June 2020 as “Dr. Don Deieso, the CEO of WIRB-Copernicus Group and a Senior Advisor of Arsenal,” in connection with a PharmaVOICE discussion on how COVID-19 was reshaping clinical-trial operations and R&D.

Deieso led WCG, the WIRB-Copernicus Group, through a period in which the company positioned itself around clinical-trial quality, efficiency, ethics review, data, and technology-enabled research services. WCG’s history states that the company was founded in 2012 when WIRB and Copernicus Group IRB became the founding members and namesakes of WCG; it also notes WCG’s predecessor companies’ 55-year history in independent ethical review and clinical research services.

On May 18, 2022, WCG announced that Sam Srivastava had been appointed CEO, succeeding Dr. Donald Deieso upon Deieso’s retirement. In that announcement, Deieso commented on WCG’s role in shaping the clinical-trials sector and on Srivastava’s fit to lead the company through its next growth phase.

I did not find a verified public source for Deieso’s education, a current LinkedIn profile, a direct headshot image, or a current personal investment page.

• Arsenal’s firm-level focus is not seed angel investing; it is private equity company-building in healthcare and industrial growth.
• Arsenal says it specializes in building “market-leading industrial growth and healthcare companies” that are technology- and innovation-rich.
• In healthcare, Arsenal says it seeks to build businesses that create “systematic improvement in health outcomes.”
• Arsenal’s healthcare focus includes pharma services, clinical research, commercial enablement, specialty pharmacy enablement, healthcare technology and services, clinical and economic optimization, employer health technology, and value-based care.
• Deieso’s most clearly documented domain expertise is clinical research infrastructure, ethical review, and clinical-trial operations through WCG / WIRB-Copernicus Group.
• A founder approaching him should treat him as a healthcare operating expert and advisor, not as a verified active seed-stage angel investor, unless a current direct investment mandate can be confirmed.